Fundraising Fox
Oxford · Pre-Seed–Growth · 71 people tracked
Find your way into Oxford Science Enterprises
Sign up to see every warm intro you have to Oxford Science Enterprises
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oxford Science Enterprises team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Oxford Science Enterprises operates as a venture builder in partnership with the University of Oxford, transforming academic breakthroughs into commercial companies. Working with researchers across Oxford, Harwell and Culham, it identifies bold scientific ideas, funds them with patient capital from pre-seed to growth stages, and builds transformational ventures. The firm focuses on deep tech, life sciences and healthtech, aiming to create world-changing, billion-pound companies while delivering strong returns for investors. It has raised over £850m from global investors and, together with co-investors, has deployed more than £3bn across its portfolio of flagship companies.
Source: firm website, verified Sep 27, 2026.
Team · 71 people
from the firm's website & curated & public directories
Katherine Ward is an Operating Partner at Oxford Science Enterprises, where she focuses on venture building in health technology. She has more than 30 years of global healthcare experience spanning the government and private sectors, with expertise in general management, business development, strategy, and team building.
Claire Brown has over 20 years of biopharmaceutical experience across the UK and US, spanning R&D strategy, licensing, business development and corporate investment. At OSE she leads company creation and portfolio strategy in Life Sciences, having joined in 2020 after roles at UCB, Sanofi-Genzyme, AstraZeneca and as Head of Investment at Pioneer Group.
Heather leads OSE's HealthTech investment team across digital health, diagnostics, medical devices and life science tools, with over 20 years in healthcare innovation and venture investing. Before joining OSE in 2022 she was a Partner at Optum Ventures leading its Global HealthTech fund, and previously held roles at Unilever and Johnson & Johnson; she holds a PhD in Clinical Biochemistry from Queen's University Belfast.
Jack Edmondson leads OSE's investment strategy and oversees all investment activity across Life Sciences, Deep Tech and HealthTech. He joined in 2023 after 14 years as Deputy CIO at Oxford University Endowment Management, and previously worked at Exponent Private Equity, McKinsey and Merrill Lynch. He holds an Oxford MBA, a Durham BA, and is a CFA Charterholder who also teaches finance at Oxford's business and government schools.
A HealthTech operator turned investor who joined OSE from Pitango, where he was an investment principal on early-stage HealthTech deals. Earlier he was a founding team member and VP of Strategy and BD at Healthy.io, and previously advised Nigeria's Ministry of Health on healthcare financing.
Sam Harman leads OSE's Deep Tech investment team, overseeing the pipeline, supporting new company creation and guiding portfolio growth, with experience across AI, semiconductors, compute and space. He joined OSE in 2019 after working in management consulting on AI solutions, and holds a first-class master's in PPE from the University of Oxford.
Sanne De Jongh invests across therapeutic areas and development stages with over a decade of biotech VC experience. She joined OSE in February 2023 after roles at Gilde Healthcare, Anterra Capital and M Ventures, and holds degrees from Leiden University and Delft University of Technology.
George Todd is a Principal at Oxford Science Enterprises. He invests in deep tech companies from pre-seed to Series B stages and serves as a non-executive director and venture builder.
Sally Dewhurst focuses on creating new biotech businesses, drawing on deep oncology research expertise to translate cutting-edge science into company formation. She joined OSE in February 2021, following a post-doctoral fellowship at Rockefeller University and a PhD at the Francis Crick Institute, and has also studied corporate finance at NYU.
Andrew Straiton is a Senior Associate in Deep Tech at Oxford Science Enterprises, where he invests across the physical sciences and engineering, with a focus on energy and industrials. He holds a PhD in applied inorganic materials chemistry from the University of Bath and previously worked as a management consultant at Bain and Company.
Antonia Jenkinson is Chief Financial Officer at Oxford Science Enterprises, working in the science and technology sector across areas including frontier science, fusion energy, and space. Her background spans corporate finance and leveraged private equity-backed companies, with five exit transactions completed in CFO and Non-Executive Director capacities. She holds four Non-Executive Director and Chair of Audit positions and has received the Sunday Times NED award.
Athene Blakeman is General Counsel at Oxford Science Enterprises, with in-house and corporate finance experience spanning 16 years, including roles at top private practice firms. From 2014 to 2019, she served as General Counsel, Company Secretary and Executive Team member of Benchmark Holdings plc, an AIM-listed international aquaculture and biotechnology group, before becoming Managing Director of Benchmark Advanced Nutrition and CEO of INVE Aquaculture, a $100m turnover aquaculture nutrition business, from 2019 to 2021. Her work covers corporate governance, listed company obligations, share schemes, commercial contracts, risk management, compliance, intellectual property, litigation, and M&A and fundraising transactions.
Charo Bajo is Data & Projects Manager at Oxford Science Enterprises. Her background includes programme leadership at operational and strategic levels, along with external and internal engagement within networked organisations, and she has developed capability programmes in Tanzania, India, China, and the Philippines. She holds a Lean Six Sigma Green Belt Practitioner certification.
Daoud Khan is a CIMA-qualified finance professional with over five years of experience across multi-entity, start-up, and investment fund settings. As Finance Manager at Oxford Science Enterprises, a £1 billion venture capital firm, he oversees fund-level reporting, valuations, and audits, and works with senior leadership on budgeting, forecasting, and performance management. His secondment work has included developing revenue-recognition playbooks, 13-week cashflow models, and board reporting materials.
Harry Clifford is a biotech entrepreneur focused on digital biology and AI, currently serving as an Entrepreneur in Residence at Oxford Science Enterprises. His prior experience includes developing healthcare products at NVIDIA and co-founding a Y Combinator-backed precision oncology startup. He completed a PhD at the University of Oxford and a postdoctoral position at the University of Cambridge.
Jon Wall is Portfolio Talent Lead at Oxford Science Enterprises, an independent investment company and venture builder that develops companies based on scientific research. In his role, he works with investors and portfolio companies to build leadership teams for deep tech enterprises across sectors including energy transition and decarbonisation, quantum computing, AI, space tech, and health tech.
Lisa Bedwell is Head of Marketing at Oxford Science Enterprises, which she joined as Senior Communications Manager in September 2020. She previously served as Communications Manager at Medicines Discovery Catapult and has over ten years of experience in the pharmaceutical and biotechnology industries, including work with US-based biotech start-ups. She holds a BSc in Psychology and an MSc in Developmental Cognitive Neuroscience from Durham University.
Mark Chadwick is a Scientist in Residence at Oxford Science Enterprises, where he works with academics and founders to commercialize research from Oxford University. He previously spent 15 years as a research scientist in academia at universities in the UK and mainland Europe, running his own research programme, publishing peer-reviewed articles, and securing research grants and fellowships.
Martin Fiennes is a Deep Tech Advisor at Oxford Science Enterprises, a £850 million investment company that develops and scales spinouts from research across the Mathematical, Physical, Life Sciences, and Medical Sciences divisions at the University of Oxford. He serves as a Non-Executive Director.
Matt Myers is a Senior Associate at Oxford Science Enterprises and a Chartered Engineer. He has experience in venture capital and engineering, along with project and people management.
Matthew Nicholls is Senior Tutor at St John's College, Oxford, and a Visiting Professor of Classics at the University of Reading, where he worked from 2007 before taking up his Oxford role in 2019. He holds MA, MPhil, and DPhil degrees from the University of Oxford, received a National Teaching Fellowship in 2017 and a Guardian/Higher Education Academy teaching award in 2014, and was elected a Fellow of the Society of Antiquaries in 2023. His research focuses on the city of Rome, including a digital 3D reconstruction of the ancient city, and on ancient books and libraries in the Roman world, and he has authored 30-Second guides to Ancient Rome and Ancient Greece.
Rachel McKee is a Senior People Advisor at Oxford Science Enterprises, where she provides advisory, strategic, and administrative support across the employee life cycle. Her responsibilities include recruitment, onboarding, benefits, payroll, and wellbeing.
Sami Walter is a Senior Investment Associate at Oxford Science Enterprises. Walter's work focuses on venture building and investing in early-stage deep tech companies.
Ed Bussey is CEO of Oxford Science Enterprises, joining in September 2023 with over 20 years of business leadership and venture-building experience. A serial entrepreneur, he founded and exited three technology businesses (figleaves.com, ZYB, and Quill) and sits on the Oxford-Cambridge SuperCluster Board. He studied finance at INSEAD and holds a BA in Natural Sciences from Cambridge.
Katharina supports the creation and growth of biotech ventures, drawing on her background in biochemistry and immunology. She holds a PhD in Immunometabolism and an MRes from the University of Cambridge and a BSc from the University of Leeds, joined OSE in May 2023, and previously interned in life science investment at Cambridge Innovation Capital.
A venture capitalist with over 20 years in biotechnology, Katya joined Oxford Science Enterprises in September 2021 and leads the Life Sciences team, supporting academic founders from early development to go-to-market. She previously worked at Alta Partners and Capricorn Partners and is a former Vice-Chair of InvestEurope. She holds a PhD in Cellular & Molecular Biology from the University of Wisconsin-Madison and completed a post-doc at Stanford University School of Medicine.
Founder mafia
3 people who came through Oxford Science Enterprises went on to found or lead other companies.
What they invest in
from 63 of 104 portfolio companiesDeep Tech ×35AI & Machine Learning ×29Biotech ×24Hardware ×18Healthtech ×18Medical Devices ×16Cleantech ×10Digital Health ×9
HQs:United Kingdom×35United States×4Luxembourg×1
Who they back
founder profiles across 26 portfolio companiesFounding team size:solo founder×102 founders×83 founders×14+ founders×7
Where their founders studiedfrom 19 founders with education data
University of Oxford ×8Imperial College London ×2
What their founders studiedfrom 25 founders with field-of-study data
Engineering ×8Physics ×7Chemistry ×4Computer Science ×3Life Sciences ×3Medicine ×3Mathematics & Statistics ×2
Where their founders worked beforefrom 27 founders with career history
University of Oxford ×15IBM ×2
21 founders hold a PhD (of 25 with degree data)
Investments · 104 tracked
founders shown can be your intro pathBy year:2026 · 52025 · 42024 · 22023 · 62022 · 42021 · 32019 · 125 dated
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies designed to guide T cells to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechMedical Devices
Geoffrey Lynn(Chief Scientific Officer)inWilliam Enright(Chief Executive Officer & Board Director)Leon Hooftman(Chief Medical Officer)inBill EnrightinAdrian Hill(Founder)Sarah Gilbert(Founder)
Co-investorsFuture Planet CapitalGV (Google Ventures)Gilead SciencesKorea Investment PartnersMilltrust International GroupTencent Holdings+1 more
PepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
James McArthur(Executive Officer, Director)inNoel P. Donnelly(Chief Financial Officer)inJoseph D. Vittiglio(Chief Business & Legal Officer and Secretary)inKasra Kasraian(Chief Technical Officer)in
BoardRamin Farzaneh-Far(Director)inJoshua Resnick(Director)
Co-investorsRA CapitalViking Global
Beacon Therapeutics develops gene therapies for patients with serious diseases that lack or have limited treatment options, including investigational products like laru-zova for genetic conditions.
BiotechDigital HealthMedical Devices
Daniel Chung(Chief Medical Officer)inLance Baldo(Chief Executive Officer)inAbraham Scaria(Chief Scientific Officer)in
Co-investorsAdvent Life SciencesForbionTCG Crossover
Sereact builds AI foundation models that enable industrial robots to perform complex manipulation tasks like warehouse picking and returns handling without retraining.
Advanced ManufacturingAI & Machine LearningDeep TechEnterprise SoftwareQuantum ComputingRoboticsOxford, GB
Ralf Gulde(CEO and co-founder)Marc Tuscher(CTO and co-founder)Gerald Mullally(CEO)
Co-investorsAlpha EdisonBritish Business BankChevron Technology VenturesInvusBackstage AB
Dark Blue Therapeutics develops novel medicines for cancer through integrated drug discovery combining internal expertise with academic partnerships.
BiotechDeep TechHealthtechLondon, GB
Alastair MacKinnon(Chief Executive Officer)in
OMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs.
BiotechDeep TechDigital HealthHealthtechMedical DevicesOxford, GB
Professor Dame Carol Robinson(Founder and Chair of Scientific Advisory Board)Idlir Liko(Founder)inJonathan Hopper(Vice President, Platforms and Founder)inHsin Yung (Jason) Yen(Founder)inRos Deeganin
Co-investorsGV (Google Ventures)Sanofi VenturesNorthpond Ventures
Opsydia develops optical and photonic technologies for precision manufacturing, emerging from research in adaptive optics and laser processing at the University of Oxford.
Advanced ManufacturingAI & Machine LearningDeep TechHardwareNew MaterialsSemiconductorsOxford, GB
Martin Booth(Founder and Director)inPatrick Salter(Founder and Director)inDr. Noel Moore(Chief Technology Officer)
BoardNigel Vaughan(Chairman)
Co-investorsForesight GroupOxford University InnovationParkwalk Advisors
Oxford Quantum Circuits (OQC) develops and operates superconducting quantum computers for commercial and strategic applications, offering Quantum-Compute-as-a-Service and integrating quantum systems directly into commercial data centres.
Deep TechEnterprise SoftwareHardwareQuantum ComputingOxford, GB
Peter Leek(Founder & CSO)inGerald Mullally(CEO)inSimon Phillips(CTO)inNikki Cooper(CLO)inRobert Coutts(CFO)in
BoardJack Boyer(Chairman of the Board)
Co-investorsBritish Business BankOxfordOxford Investment Consultants LLPUTEC
Refeyn develops mass photometry instruments that measure the mass of individual biomolecules in solution without labels, enabling analysis of protein purity, interactions, and viral vector characterization for research and manufacturing applications.
BiotechDeep TechHardwareMedical DevicesOxford, GB
Philipp Kukura(Founder)Dan Cole(Chief Scientist and co-founder)inJustin Benesch(Co-founder)in
Co-investorsForesight GroupHorizons VenturesOxford Technology Management
Seloxium develops a metal recovery and refining technology (branded "Selectal") used for tailings reprocessing, wastewater treatment, bulk metal recovery, and high-purity refining.
Circular EconomyCleantechDeep TechNew MaterialsTeesside, GB
Christian Peters(CEO & Co-founder)inSteve Colley(Co-founder, Technical Advisor & Director)Nick Hankins(Co-founder, Scientific Advisor & Director)Steve van Zutphen(Co-founder, CEO Advisor)Dr Richard Dixon(CCO)Roberto Ricci(CFO)in
Co-investorsOxford Investment Opportunity Network (OION)Empirical Ventures
Singular Machines develops AI-native engineering tools for designing complex machines, facilities, and infrastructure in the advanced manufacturing sector.
Advanced ManufacturingAI & Machine LearningDeep Tech
Co-investorsUK Innovation & Science Seed Fund
Sitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism.
BiotechDeep TechHealthtech
Co-investorsLongwood FundSofinnova PartnersSV Health InvestorsDementia Discovery Fund
Snow Fox Discovery explores for and develops natural (geologic) hydrogen resources, aiming to supply low-carbon hydrogen for a net-zero energy transition.
CleantechClimate TechEnergy
Daniel McMahonin
Co-investorsAP VenturesOxfordbp ventures
Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment.
BiotechHealthtech
Co-investorsEpidarex CapitalSound BioventuresTaiho Ventures, LLCM Ventures
Ultromics develops AI models that analyze routine echocardiography studies to help clinicians detect HFpEF and screen for cardiac amyloidosis, delivered through a single workflow platform.
AI & Machine LearningDigital HealthMedical Devices
Ross Upton(Founder & CEO)in
Co-investorsGV (Google Ventures)Legal & GeneralFuture Planet CapitalNina CapitalNovaCapitalOptum Ventures+4 more
Allos offers an AI platform that simulates how process interventions affect outcomes to define robust operating windows before physical experiments are run, supporting pharmaceutical development from formulation through scale-up, tech transfer, QA, and clinical trials.
AI & Machine LearningBiotechHealthtech
Co-investorsOxford University Innovation
AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.
BiotechDeep TechDigital HealthHealthtechMedical Devices
David Hipkiss(Executive Chair)in
Co-investorsOld College Capital
Amber Therapeutics develops medical technology focused on treating mixed urinary incontinence, advancing toward pivotal clinical trials in the US with expanded feasibility studies in Europe.
Medical Devices
Co-investorsF-Prime CapitalIntuitive VenturesLightstone VenturesNew Enterprise Associates (NEA)
Archangel builds laser (optical) communication systems that connect satellite networks in space with terrestrial networks, offering an alternative to radio frequency and subsea cable infrastructure.
Deep TechHardwareSpace Tech
Co-investorsBlackfinch VenturesOxford
BehaVR develops VR-based (XR) therapeutics for mental and behavioral health, translating clinical science into immersive programs that address stress, anxiety, fear, pain management, addiction recovery, and maternal health.
Digital HealthHealthtechMental HealthElizabethtown, US
Aaron Gani(Executive Officer, Director)
Co-investorsChrysalis VenturesKeyhorse CapitalPoplar VenturesAccenture VenturesFrist Cressey VenturesFuture Labs Capital+1 more
BibliU is a digital learning platform that partners with publishers to provide students affordable, instant access to course content, and offers institutions workflow automation to reduce administrative burden.
EdTechSaaS
Dave Sherwood(CEO & Co-Founder)in
.avif)
Co-investorsBrick Capital VenturesGreen Shores CapitalGuinness VenturesKreos CapitalParkwalk AdvisorsBeyond Ventures+4 more
University of Oxford spinout whose imaging technology aids diagnosis and treatment of cardiovascular disease.
Co-investorsBusiness Growth FundCreative Destruction Lab (CDL)Longwall Venture Partners LLPOxford Investment Consultants LLP
Covatic develops an on-device advertising platform powered by AI and machine learning that identifies user cohorts and delivers targeted ads while preserving consumer privacy.
AdTechAI & Machine LearningIoTLondon, GB
Nick Pinks(Founder)in
Co-investorsCreative UKOxford Technology ManagementTechstarsTechstars Ventures 2022
Densix develops high power-density power converters aimed at applications including data centres, power grids, EV charging, and renewable energy.
CleantechEnergyHardware
Co-investorsOxford University Innovation
Endlyz develops small-molecule disease-modifying therapeutics targeting the ATP13A2 and ATP10B lysosomal transporters to restore endo-lysosomal function and counter neurodegeneration.
BiotechDeep TechBoston, US
Joanna Wolak(Executive Officer, Director)inJonathan Behr(Director)John Gustofson(Director)Damian Crowther(Director)Zaven Kaprielian(Executive Officer, Director)
BoardLaurence Barker(Director)
Co-investorsDementia Discovery Fund
Evolito develops and manufactures electric propulsion and power generation systems for aerospace, including electric engines, motors, and motor control systems for type-certifiable and volume-manufactured applications.
CleantechHardwareMobility & Transportation
Co-investorsPerivoli Innovations
Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases.
BiotechDeep Tech
Co-investorsGV (Google Ventures)OrbiMedPanacea VentureCowen Healthcare InvestmentsREDMILE
First Light Fusion develops fusion energy technology through experimental validation of projectile-based fusion concepts and computational modeling for inertial confinement fusion applications.
CleantechDeep TechEnergyOxfordshire, GB
Yiannis Ventikos(Founder)Nicholas Hawker(Founder)
Co-investorsSalica InvestmentsIP Group
FluoRok, a spin-out of the University of Oxford, develops patented fluorinating technologies to produce fluorochemicals such as Li-ion battery electrolytes, agrochemicals, and pharmaceutical ingredients without generating toxic hydrofluoric acid.
CleantechDeep TechNew Materials
Gabriele Pupo(CEO & Founder)inVéronique Gouverneur(Founder)in
Co-investorsExcellis HoldingGGFGreen Generation FundBusiness Growth FundClub degli InvestitoriePlanet Capital
Fractile designs processors for AI acceleration, offering the next generation of computing hardware.
AI & Machine LearningDeep TechHardwareSemiconductorsBristol, GB
Walter Goodwin(Founder & CEO)in
Co-investors01 AdvisorsAccelFactorial FundsFelicis VenturesGigascale CapitalInovia Capital+10 more
Genomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers.
AI & Machine LearningBiotechDigital HealthHealthtechOxford, GB
Peter Donnelly(Founder)inDr Chris Spencer(Founder)Dr Gerton Lunter(Founder)Gilean McVean(Founder)Professor Gil McVean(Founder)Professor Sir Peter Donnelly(Founder)
Co-investorsF-Prime CapitalForesite CapitalSalica InvestmentsIP Group
Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.
BiotechDigital HealthHealthtechMedical DevicesOxford, GB
Peter Joyce(Co-founder)inTom McCarthy(Co-founder)in
Co-investorsAndera PartnersCanaan PartnersPfizer Venture InvestmentsBritish Patient CapitalEarlybird Venture CapitalPfizer Ventures
Delivering single cells to advance research and medicine
Co-investorsFuture Planet CapitalOxford Investment Opportunity Network (OION)
Living Optics develops hyperspectral imaging cameras and software that enable users to capture and analyze hidden details in images across applications in food, healthcare, security, and industrial markets.
AI & Machine LearningDeep TechHardwareMedical DevicesOxford, GB
Co-investorsOctopus Ventures
Marley Health combines veterinary and human healthcare expertise with machine learning and technology to develop healthcare solutions.
AI & Machine LearningConsumerHealthtechMedical Devices
Nate Notwell(Co-founder & CEO)Dr Amanda Boag(Co-founder & CMO)Dr Jenny Wilshaw(Co-founder & Head of Data)Prof David Clifton(Co-founder & Technology Advisor)
Mind Foundry develops deployed AI and machine learning systems for high-risk, high-complexity operational domains, including defense applications such as multi-sensor data fusion for battlespace situational awareness and threat-signature analysis.
AI & Machine LearningDeep TechDefense Tech
Stephen Roberts(Co-founder)inMichael Osborne(Co-founder)
Co-investorsParkwalk Advisors
Mixergy manufactures smart hot water cylinders with patented heating technology and machine learning controls that reduce energy consumption by up to 40%.
CleantechClimate TechEnergyHardwareIoTUK, GB
Pete Armstrong(Founder)Ren Kang(Founder)
Co-investorsEDP VenturesIP GroupKiko Ventures
NavLive provides a handheld scanning device and cloud platform that captures point clouds and generates 2D floor plans, elevations, and sections in real time using multi-sensor SLAM tracking and AI feature detection.
AI & Machine LearningConstruction TechHardwarePropTech
David Wisth(Founder)in
Co-investorsClearance Venture PartnersOxfordSOSVTrimble Ventures
Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.
AI & Machine LearningBiotechDeep Tech
Co-investorsM VenturesPfizer Venture InvestmentsBritish Patient CapitalJJDCPfizer Ventures
nVisiq develops passive 3D perception systems designed for long-range, high-resolution sensing that operates across varied and difficult environments.
AI & Machine LearningDeep TechHardware
Co-investorsCelero Ventures Ltd.
ONI develops the Nanoimager, an automated super-resolution imaging system.
BiotechDeep TechHardwareMedical DevicesOxford, GB
Co-investorsAnjostARCH Venture PartnersArtis VenturesFuture Planet CapitalOxford Technology ManagementVertical Venture Partners+6 more
Orbit Discovery provides peptide discovery solutions for pharmaceutical and biotechnology companies, serving both large pharmaceutical firms and smaller biotech enterprises.
AI & Machine LearningBiotechDeep TechHealthtechOxford, GB
Neil Butt(CEO)in
Co-investorsFuture Planet CapitalOxford Technology ManagementPerivoli InnovationsBorealis Ventures
ORCA Computing develops full-stack photonic quantum computing systems, including on-premises hardware and software tools, for research institutions, government bodies, and industry applications such as generative AI, machine learning, and optimisation.
AI & Machine LearningDeep TechHardwareQuantum ComputingLondon, GB
Ian Walmsley(Founder)inRichard Murray(Founder)inJosh Nunn(Founder)inPer Nyberg(Chief Commercial Officer)inMike Piraino(Chief Operating Officer)Thien-An Nguyen(Chief Technology Officer)in
Co-investorsInnovating CapitalOctopus VenturesPerscitus LLPQuantonationVerve VenturesAtmos capital
.jpeg){kind=logo}
Oxford Flow manufactures precision valves and regulators using a single-piston design for oil & gas, hydrogen, and water infrastructure.
Advanced ManufacturingCleantechEnergyHardwareOxford, GB
Co-investorsEnergy Impact PartnersFuture Planet Capitalbp ventures
Oxford Ionics develops trapped-ion quantum computers using proprietary Electronic Qubit Control technology, designed for businesses to deploy quantum computing applications.
Deep TechHardwareQuantum Computing
Co-investorsOxford University Innovation2xNBraavos CapitalLansdowne PartnersProsus VenturesProvidence Investment Company Limited
Oxford Semantic Technologies develops RDFox, an in-memory knowledge graph and semantic reasoning engine that uses logic-based inference to deduce new facts and deliver explainable, auditable results for AI applications.
AI & Machine LearningData & InfrastructureDeep TechOxford, GB
Perspectum develops digital medical technology and diagnostics using multiparametric MRI to assess and diagnose chronic systemic diseases including liver disease, long COVID, diabetes, and cancer for clinicians and patients.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesOxford, GB
Rajarshi Banerjee(CEO)in
Co-investorsBlue Venture FundsBritish Patient CapitalHealthQuest CapitalSandbox Industries
PQShield develops post-quantum cryptography (PQC) products, including optimized software libraries, SDKs, OpenSSL integration layers, and lattice-based hardware IP cores, to help organizations migrate systems to quantum-resistant cryptography.
CybersecurityDeep TechQuantum ComputingSemiconductors
Co-investorsBY Venture PartnersCrane Venture PartnersKindred CapitalAdditionChevron Technology Ventures
Prolific connects researchers, AI developers, and product teams with vetted participants for collecting high-quality human data for AI training, surveys, and behavioral research.
AI & Machine LearningData & InfrastructureEnterprise SoftwareMarketplacesSaaSLondon, GB
Phelim Bradley(CTO)inSam Harman(Director)Enrico D'Angelo(Director)Meenakshi Parameshwaran(Data Scientist)Matt Tuplin(Vice President of Engineering)Chloe Sheppard(Talent Manager)
Co-investors10xvaluepartnersY CombinatorAltaclub VCAltaIR CapitalPartech VenturesPioneer
Prolific operates an online platform connecting researchers and AI/ML developers with verified human participants who complete paid studies, providing human data and feedback for research and for AI tasks like preference tuning, safety evaluations, and benchmarks.
AI & Machine LearningData & InfrastructureMarketplaces
Co-investorsPartech VenturesPioneer
Proxisense develops high-performance sensors for monitoring manufacturing processes and diagnostics, with origins in aerospace and defence applications.
Advanced ManufacturingDeep TechHardwareIoTMedical DevicesOxford, GB
Paul Vickery(Founder and Chairman)Kam Chana(Founder and NED)
Co-investorsFuture Planet CapitalParkwalk Advisors
Quantum Motion develops utility-scale quantum computers using silicon spin-qubit architecture compatible with standard semiconductor manufacturing processes and existing foundry supply chains.
Deep TechQuantum ComputingSemiconductors
Co-investorsBosch VenturesDCVC (Data Collective)InkefOctopus VenturesSony Ventures CorporationBritish Business Bank+2 more
RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.
BiotechHealthtech
Co-investorsFrazier Life SciencesLifeArc VenturesWellington ManagementEQT Life SciencesForbionMonograph Capital Partners+1 more
Spin-out from the Universities of Oxford and Munster developing a novel semiconductor chip.
Vaysh Kewada(Founder)in
Co-investorsBorski FundCambridge Innovation CapitalPerivoli InnovationsSilicon CatalystApplied VenturesDeeptech Labs
Scenic Biotech develops modifier therapy, a genetic medicine approach that targets secondary functions in the genome to neutralize the impact of disease-causing mutations.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Co-investorsBioGeneration VenturesBioMedPartnersEIR VenturesInkef
Scripta Therapeutics is a drug discovery company that maps and modulates transcription factors using AI/ML models and patient-derived disease models to identify novel therapeutics.
AI & Machine LearningBiotechDeep Tech
Co-investorsAlbionVCApollo Health Ventures
A biotech company dedicated to developing new vaccines, combining scientific expertise with commercial and operational capabilities.
BiotechDeep TechHealthtechMedical DevicesCambridge, GB
Mark Howarth(Co-founder)inSumi Biswas(President, Co-founder, Chief Scientific Officer)inSimon Draper(Co-founder)inJing Jin(Co-founder)in
Co-investorsGV (Google Ventures)Braavos CapitalOxford
Stateful builds a decision intelligence engine that turns operational requirements into optimised, adaptive missions for mobile robots, coordinating single-robot, multi-robot, and human-robot operations across changing real-world environments.
AI & Machine LearningDeep TechRobotics
Kirsty Lloyd-Jukes(CEO & Co-Founder)inNick Hawes(Chief Scientist & Co-Founder)Bruno Lacerda(CTO & Co-Founder)inDavid Parker(Advisor & Co-Founder)
Co-investorsAmadeus Capital PartnersOxford University InnovationAmadeus Capital SA
T-Cypher Bio develops drugs with curative potential, focusing on antibody development, T cell biology, and TCR discovery.
AI & Machine LearningBiotechDeep Tech
Co-investorsFuture Planet CapitalLifeArc VenturesPerivoli InnovationsMedicxi
Tidal Cyber develops tools and services that help enterprises adopt MITRE ATT&CK framework for threat-informed defense.
CybersecurityEnterprise Software
Rick Gordonin
Co-investorsAccess Venture PartnersBright Pixel CapitalDreamit VenturesGlasswing VenturesStoneMill VenturesTFX Capital+10 more
Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
Arne Scheu(Founder)inIrsyad Khairil(Founder)in
Co-investorsHoxton VenturesLongeVCMetaplanetOxonian VenturesP53 InvestRV Invest GmbH+9 more
Vivid provides mobile business and personal banking for European small and medium-sized companies, offering online account opening, instant transfers, interest on cash balances, cashback cards, and investment options in stocks, ETFs, and cryptocurrencies.
FintechSaaS
Alex Emeshev(Founder)in
Co-investorsSoftBank Vision FundGreenoaksRibbit Capital
YASA designs and manufactures axial-flux electric motors for automotive OEM customers such as Ferrari and Lamborghini, operating an axial-flux factory in Oxfordshire, UK.
Advanced ManufacturingCleantechHardwareMobility & TransportationOxford, GB
Tim Woolmer(Founder & CTO)inJörg Miska(Chief Executive Officer)
Co-investors24 HaymarketParkwalk AdvisorsInovia Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Acionna TherapeuticsAlethio TherapeuticsAlethiotxAlloyedApplied AtomicsAscensionBase GenomicsBeacon TherapeuticsCaudal EnergyCircadian TherapeuticsCredo TherapiesDJS AntibodiesELIGENTISExposing cancer’s hidden vulnerabilitiesGround Truth LabsHEXRISOgenixKesmaleaKneu HealthLatent LogicMatchBioMirae HealthMiroBioMoa TechnologyNatcapOath SurgicalOdqa Renewable Energy TechnologiesORFonyxOsler DiagnosticsOxford EndovascularOxford NanoimagingRinri TherapeuticsSalienceScriptaStronger, lighter, fasterThelior BioVivid Dx
Exits · 3
2 IPOs · 1 acquisitionsBarinthusbioNASDAQ: BRNSPepGenNASDAQ: PEPGYasaacq. by Mercedes Benz
Portfolio news
latest coverage across their companies
Fractile · thenextweb.com · Aug 19, 2026
Refeyn · refeyn.com · Aug 11, 2026
PepGen · stocktitan.net · Aug 6, 2026
RQ Bio · finsmes.com · Jun 24, 2026
Bibli U · finsmes.com · Jun 3, 2026
Seloxium · cen.acs.org · Jun 2, 2026
First Light Fusion · finance.yahoo.com · Apr 10, 2026
Frequently asked questions
- How many investments has Oxford Science Enterprises made?
- Oxford Science Enterprises has 104 tracked investments, 3 of which have exited, including 9 dated in the last 24 months.
- What stage does Oxford Science Enterprises invest at?
- Oxford Science Enterprises invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth stages.
- What is Oxford Science Enterprises's typical check size?
- Oxford Science Enterprises typically writes checks of $63.5K – $31.8M.
- What sectors does Oxford Science Enterprises focus on?
- Oxford Science Enterprises focuses on AgTech, AI & Machine Learning, Biotech, Cleantech, Climate Tech, Deep Tech, Energy, Healthtech, Medical Devices, Quantum Computing, Robotics, Sector Agnostic.
- Where is Oxford Science Enterprises located?
- Oxford Science Enterprises is headquartered in Oxford, GB.
- Does Oxford Science Enterprises lead rounds?
- Yes, Oxford Science Enterprises leads investment rounds.
- Who does Oxford Science Enterprises co-invest with?
- Oxford Science Enterprises most often shares deals with Future Planet Capital, Perivoli Innovations, GV (Google Ventures), among 93 tracked co-investors.
Media · Podcasts & interviews
featuring the teamFII9: Ed Bussey – CEO, Oxford Science Enterprises
FII Institute · Ed Bussey
Ed Bussey, CEO of Oxford Science Enterprises, on the need for talent in the UK's spinout ecosystem.
Global Corporate Venturing · Ed Bussey
Ed Bussey, CEO, Oxford Science Enterprises
American European Business Association - AEBA · Ed Bussey
Bloomberg Talks: Oxford Science Enterprises CEO Ed Bussey | Bloomberg Talks
Bloomberg Podcasts · Ed Bussey
Images
Co-investors · 4
Parkwalk Advisors is a UK-based investment manager focused on backing deeptech companies spun out of UK universities, bridging the gap between academic research and commercial success. It operates as part of IP Group plc and is a leading EIS fund manager.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Apollo Health Ventures is a biotech-focused investor that combines traditional funding with venture building to back transformative healthcare and longevity companies in Europe and the US.
Borealis Ventures is a venture capital firm focused on building and investing in visionary healthcare companies.
Firms observed investing alongside Oxford Science Enterprises, from public investor directories. Shared companies are the overlap with Oxford Science Enterprises's recorded portfolio.
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Artesian is a deep tech and hardware venture capital investor that builds funds around specific institutional backers — governments, corporations, universities, industry bodies and super funds — to pursue both financial returns and strategic outcomes in critical industries.
The Business Development Bank of Canada (BDC) is a Canadian institution that has supported small and medium-sized businesses for over 80 years, providing financing and advisory services to companies across all industries and growth stages.
Innovation Industries is a Dutch deep-tech venture capital firm that builds and scales technology companies through hands-on, multidisciplinary support.